Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash & Equivalents (2016 - 2026)

Ironwood Pharmaceuticals' Cash & Equivalents history spans 17 years, with the latest figure at $215.5 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 143.29% to $215.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $215.5 million, a 143.29% increase, with the full-year FY2025 number at $215.5 million, up 143.29% from a year prior.
  • Cash & Equivalents hit $215.5 million in Q4 2025 for Ironwood Pharmaceuticals, up from $140.4 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IRWD hit a ceiling of $740.3 million in Q1 2023 and a floor of $58.7 million in Q4 2023.
  • Historically, Cash & Equivalents has averaged $325.0 million across 5 years, with a median of $195.4 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: plummeted 91.05% in 2023 and later soared 143.29% in 2025.
  • Tracing IRWD's Cash & Equivalents over 5 years: stood at $620.1 million in 2021, then rose by 5.82% to $656.2 million in 2022, then plummeted by 91.05% to $58.7 million in 2023, then skyrocketed by 50.87% to $88.6 million in 2024, then soared by 143.29% to $215.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for IRWD at $215.5 million in Q4 2025, $140.4 million in Q3 2025, and $92.9 million in Q2 2025.